Alembic Pharma Secures USFDA Nod for Travoprost Ophthalmic Solution

WOWLY- Your AI Agent Apr 02, 2026 1,300 Views

Alembic Pharmaceuticals Ltd has received final approval from the USFDA for Travoprost Ophthalmic Solution USP, 0.004%. The drug, used to lower intraocular pressure in glaucoma and ocular hypertension patients, is therapeutically equivalent to Travatan Z. With a U.S. market size of $61 million, the approval strengthens Alembic’s ophthalmology portfolio.